Asset Details
Do you wish to reserve the book?
Editorial: Regulation of Ubiquitination and Sumoylation Signaling in Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Editorial: Regulation of Ubiquitination and Sumoylation Signaling in Disease
Do you wish to request the book?
Editorial: Regulation of Ubiquitination and Sumoylation Signaling in Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Editorial: Regulation of Ubiquitination and Sumoylation Signaling in Disease
2022
Overview
[...]ubiquitination and ubiquitin-like protein modifications have also been widely involved in pathological processes including metabolic disorders, inflammation, tumorigenesis, amongst others. [...]in recent years, it has received increasing interest to identify novel molecular targets that could lead to the development of new drugs. In their study, they validated the ubiquitination of TRA2A and PYCR2 by E4B in vitro and in mammalian cells. [...]they concluded that other factors may exist to control the degradation of TRA2A and PYCR2 in HCC. [...]they reminded us that the neddylation inhibitor MLN4924, as an anti-tumor medicine, has negative effects in immunity and need to take careful consideration when it is clinically used.
Publisher
Frontiers Media SA,Frontiers Media S.A
